Acute intranigral homocysteine administration produces stereotypic behavioral changes and striatal dopamine depletion in Sprague-Dawley rats

被引:20
作者
Chandra, G
Gangopadhyay, PK
Kumar, KSS
Mohanakumar, KP
机构
[1] Indian Inst Chem Biol, Div Clin & Expt Neurosci, Kolkata 700032, W Bengal, India
[2] Bangur Inst Neurol, Kolkata 700025, W Bengal, India
关键词
folic acid metabolism; L-DOPA side effect; homocysteine; Parkinson's disease; stereotypic behavior;
D O I
10.1016/j.brainres.2005.12.073
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Homocysteine has been considered a major risk factor for cardiovascular diseases, and patients with hyperhomocystinemia exhibit neurological and psychological abnormalities. Elevated level of this molecule in the blood of Parkinson's disease patients receiving long-term L-DOPA therapy prompted us to investigate whether homocysteine is neurotoxic to the nigrostriatal dopaminergic system in Sprague-Dawley rats. Animals infused unilaterally with different doses of homocysteine (0.25-1 mu mol in 1 mu l) intranigrally exhibited significant and dose-dependent decrease in dopamine levels in the ipsilateral striatum as assayed employing an HPLC coupled with electrochemical detector, 19 days post-infusion. While 3,4-dihydroxyphenylacetic acid level in the striatum showed a dose-dependent decrease, homovanillic acid was found to be inhibited only for the highest dose. Amphetamine administration in these animals on the 14th day caused stereotypic turning behavior ipsilateral to the side of infusion. Apomorphine challenge on the 16th day elicited stereotypic contralateral circling behavior. Neurotransmitter levels in the serotonergic perikarya or terminals were unaltered 19 days following intraraphe infusion of homocysteine, which suggested the specificity of its action to dopaminergic neurons. These results indicate nigrostriatal lesions similar to that observed following intranigral infusion of the dopaminergic neurotoxin, 6-hydroxydopamine and suggest its closeness to the parkinsonian animal model. Furthermore, these findings provide evidence for the neurotoxic nature of homocysteine to dopaminergic neurons and suggest that elevated level of this molecule in parkinsonian patients may be conducive to accelerate the progression of the disease. (c) 2005 Elsevier B.V. All rights reserved.
引用
收藏
页码:81 / 92
页数:12
相关论文
共 76 条
[71]   Vitamin B12 and folate in relation to the development of Alzheimer's disease [J].
Wang, HX ;
Wahlin, A ;
Basun, H ;
Fastbom, J ;
Winblad, B ;
Fratiglioni, L .
NEUROLOGY, 2001, 56 (09) :1188-1194
[72]   Homocysteine and atherothrombosis [J].
Welch, GN ;
Loscalzo, J .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (15) :1042-1050
[73]   Plasma homocysteine and MTHFR C677T genotype in levodopa-treated patients with PD [J].
Yasui, K ;
Kowa, H ;
Nakaso, K ;
Takeshima, T ;
Nakashima, K .
NEUROLOGY, 2000, 55 (03) :437-440
[74]   Levodopa-induced hyperhomocysteinaemia in Parkinson's disease [J].
Yasui, K ;
Nakaso, K ;
Kowa, H ;
Takeshima, T ;
Nakashima, K .
ACTA NEUROLOGICA SCANDINAVICA, 2003, 108 (01) :66-67
[75]   Plasma homocysteine levels in L-dopa-treated Parkinson's disease patients with cognitive dysfunctions [J].
Zoccolella, S ;
Lamberti, P ;
Iliceto, G ;
Diroma, C ;
Armenise, E ;
Defazio, G ;
Lamberti, SV ;
Fraddosio, A ;
de Mari, M ;
Livrea, P .
CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2005, 43 (10) :1107-1110
[76]   Plasma homocysteine levels in Parkinson's disease: role of antiparkinsonian medications [J].
Zoccolella, S ;
Lamberti, P ;
Armenise, E ;
de Mari, M ;
Lamberti, SV ;
Mastronardi, R ;
Fraddosio, A ;
Illiceto, G ;
Livrea, P .
PARKINSONISM & RELATED DISORDERS, 2005, 11 (02) :131-133